Charles Schwab Investment Management Inc. Sells 3,321 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)

Charles Schwab Investment Management Inc. reduced its position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) by 1.1% in the fourth quarter, Holdings Channel reports. The firm owned 298,949 shares of the company’s stock after selling 3,321 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Amylyx Pharmaceuticals were worth $1,130,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Blue Trust Inc. raised its stake in Amylyx Pharmaceuticals by 232.1% in the fourth quarter. Blue Trust Inc. now owns 6,987 shares of the company’s stock valued at $26,000 after purchasing an additional 4,883 shares in the last quarter. Y Intercept Hong Kong Ltd bought a new position in shares of Amylyx Pharmaceuticals in the 4th quarter worth $56,000. Barclays PLC raised its position in shares of Amylyx Pharmaceuticals by 91.1% during the 3rd quarter. Barclays PLC now owns 84,572 shares of the company’s stock valued at $274,000 after buying an additional 40,319 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Amylyx Pharmaceuticals by 144.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 140,559 shares of the company’s stock worth $455,000 after acquiring an additional 83,048 shares during the last quarter. Finally, FMR LLC grew its position in Amylyx Pharmaceuticals by 292.0% in the third quarter. FMR LLC now owns 221,001 shares of the company’s stock worth $716,000 after acquiring an additional 164,622 shares in the last quarter. Institutional investors own 95.84% of the company’s stock.

Amylyx Pharmaceuticals Stock Down 5.4 %

Shares of AMLX opened at $3.66 on Monday. The stock has a market capitalization of $324.28 million, a P/E ratio of -0.96 and a beta of -0.51. Amylyx Pharmaceuticals, Inc. has a twelve month low of $1.58 and a twelve month high of $7.27. The firm has a fifty day simple moving average of $3.55 and a two-hundred day simple moving average of $4.04.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last posted its earnings results on Tuesday, March 4th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.06). The firm had revenue of ($0.67) million for the quarter. Sell-side analysts expect that Amylyx Pharmaceuticals, Inc. will post -2.2 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Joshua B. Cohen sold 11,851 shares of the company’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $3.47, for a total transaction of $41,122.97. Following the completion of the transaction, the chief executive officer now owns 3,201,247 shares in the company, valued at $11,108,327.09. This represents a 0.37 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Justin B. Klee sold 7,471 shares of the firm’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $4.04, for a total value of $30,182.84. Following the completion of the sale, the chief executive officer now directly owns 3,176,788 shares of the company’s stock, valued at $12,834,223.52. The trade was a 0.23 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 27,169 shares of company stock worth $97,274. 11.70% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $12.00 price target on shares of Amylyx Pharmaceuticals in a research report on Wednesday, March 5th. Three analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $7.33.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.